Stockreport

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]

Mineralys Therapeutics, Inc.  (MLYS) 
PDF – Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data – – Conference call to [Read more]